All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is pleased to present a visual abstract summarizing key results from the non-inferiority phase III ASAP trial comparing sequential conditioning prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) versus salvage chemotherapy followed by allo-HSCT in patients with poor response to first induction or relapsed/refractory acute myeloid leukemia.
The findings from the ASAP trial were recently presented by Schetelig1 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition. The findings suggest that watchful waiting along with sequential conditioning prior to allo-HSCT may improve outcomes in patients with relapsed/refractory acute myeloid leukemia and with a readily available stem cell donor.
To download this visual abstract, click below.Download here
Schetelig J. In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by allo-HCT: Results from the randomized phase III ASAP trial. Plenary scientific session #4. 64th American Society of Hematology Annual Meeting and Exposition; Dec 11, 2022; New Orleans, US.
Inhibition of the menin-KMT2A interaction in AML: The AUGMENT-101 and KOMET-001 trials
The AML Hub summarizes findings from the phase I AUGMENT-001 trial of revumenib for R/R AML and the phase I/II KOMET-001 dose escalation trial of ziftomenib,...
Visual abstract | Azacitidine with venetoclax and magrolimab in patients with ND or R/R AML
We present a visual abstract representing key data from a phase I/II trial investigating the triplet combination of azacitidine, venetoclax, and magrolimab...
Subscribe to get the best content related to AML delivered to your inbox